5MP Stock Overview
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biodexa Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.95 |
| 52 Week High | US$18.40 |
| 52 Week Low | US$0.66 |
| Beta | 1.57 |
| 1 Month Change | 3.24% |
| 3 Month Change | -19.07% |
| 1 Year Change | -94.81% |
| 3 Year Change | -99.96% |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5MP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -20.4% | -1.5% | 1.9% |
| 1Y | -94.8% | -23.6% | 4.6% |
Return vs Industry: 5MP underperformed the German Biotechs industry which returned -23.6% over the past year.
Return vs Market: 5MP underperformed the German Market which returned 4.6% over the past year.
Price Volatility
| 5MP volatility | |
|---|---|
| 5MP Average Weekly Movement | 35.0% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5MP's share price has been volatile over the past 3 months.
Volatility Over Time: 5MP's weekly volatility (35%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 21 | Stephen Stamp | www.biodexapharma.com |
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
Biodexa Pharmaceuticals Plc Fundamentals Summary
| 5MP fundamental statistics | |
|---|---|
| Market cap | €4.08m |
| Earnings (TTM) | -€8.23m |
| Revenue (TTM) | €442.92k |
9.2x
P/S Ratio-0.5x
P/E RatioIs 5MP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5MP income statement (TTM) | |
|---|---|
| Revenue | UK£381.00k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£381.00k |
| Other Expenses | UK£7.46m |
| Earnings | -UK£7.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,858.01% |
| Debt/Equity Ratio | 0% |
How did 5MP perform over the long term?
See historical performance and comparison